As decision-making continues to become more data-driven, feasibility teams must continue to strengthen their analytics techniques. Our consortium shares tips to leverage RWD using artificial intelligence and machine learning to generate insights.
There is value in having local, boots-on-the-ground teams, even in the era of big data. We explore how our feasibility teams continue to evolve and recruit the right talent, while balancing new data with institutional knowledge.
As biopharma companies continue to grow, their feasibility teams must remain nimble. Our consortium discusses issues surrounding centralized governance, shared goals and visions, data sharing, sustainable improvement and more.
It is more important than ever to connect the head and the heart. This means always putting the concerns and benefits of the patient first. To achieve this, we aim to address patient-centric trial designs, effective engagement strategies and more.